The $25 Billion Pain Market Is In Trouble (Part 4)

In this series of articles, we look at the nature of pain, a large market that remains underserved by pharmacology. The first two installments provided a taxonomy of pain types (see Part 1 and Part 2). In Part 3, we provided the first half of a look toward new methods of treatment. Here, in Part 4, the last installment, we look at the drugs, present and future, that treat pain.